Targeting stress in ovarian cancer cells to improve treatment outcomes
Enhancing endoplasmic reticulum stress in ovarian cancer
This study is looking at how a new treatment called ERX-208 can make ovarian cancer cells more stressed and possibly die off, which could help improve the way we treat this tough-to-beat cancer.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Texas Hlth Science Center NIH-funded |
| Lab location | 1 site (San Antonio, United States) |
| Project ID | NIH-11058372 on NIH RePORTER |
What this research studies
This research focuses on ovarian cancer, which is known for its high mortality rate and resistance to chemotherapy. The study investigates how ovarian cancer cells experience heightened endoplasmic reticulum (ER) stress due to their rapid growth and protein synthesis demands. By using a novel compound, ERX-208, the research aims to further increase this stress in cancer cells, potentially leading to cell death and improved treatment responses. The approach includes testing this compound on various cancer models to assess its effectiveness in reducing tumor growth.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with ovarian cancer, particularly those who have shown resistance to standard chemotherapy treatments.
Not a fit: Patients with early-stage ovarian cancer or those who have not yet undergone chemotherapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapeutic strategies that significantly improve survival rates for ovarian cancer patients.
How similar studies have performed: Other research has shown promise in targeting ER stress in cancer cells, indicating that this approach may lead to significant advancements in treatment.
Where this research is happening
San Antonio, United States
- University of Texas Hlth Science Center — San Antonio, United States (Active)
Researchers
- Principal investigator: Vadlamudi, Ratna K — University of Texas Hlth Science Center
- Study coordinator: Vadlamudi, Ratna K
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.